fulvestrant has been researched along with Recrudescence in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 5 (83.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fujita, T; Gondo, N; Hattori, M; Horio, A; Ichikawa, M; Idota, A; Iwata, H; Kondo, N; Sawaki, M; Ushio, A | 1 |
| Adachi, K; Amano, S; Enomoto, K; Fujisaki, S; Gonda, K; Masuo, Y; Matsuo, S; Nagashima, S; Sakurai, K; Suzuki, S; Tomita, R; Umeda, N | 1 |
| Adachi, K; Enomoto, K; Fujisaki, S; Gonda, K; Hara, Y; Hirano, T; Masuo, Y; Nagashima, S; Sakurai, K; Suzuki, S; Tomita, R | 1 |
| Bieche, I; Cohen, PA; Dumontet, C; Ghayad, SE; Lidereau, R; Spyratos, F; Treilleux, I; Vendrell, JA | 1 |
| Dowsett, M; Dunbier, A; Ghazoui, Z; Johnston, S; Martin, LA; Pancholi, S; Weigel, MT | 1 |
| Bergh, J; Brattström, D; Eiermann, W; Henriksson, R; Jönsson, PE; Lidbrink, EK; Lindemann, JP; Trudeau, M; Wiklund, F | 1 |
1 trial(s) available for fulvestrant and Recrudescence
| Article | Year |
|---|---|
FACT: an open-label randomized phase III study of fulvestrant and anastrozole in combination compared with anastrozole alone as first-line therapy for patients with receptor-positive postmenopausal breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Estradiol; Female; Fulvestrant; Humans; Middle Aged; Neoplasms, Hormone-Dependent; Nitriles; Receptors, Estrogen; Recurrence; Triazoles | 2012 |
5 other study(ies) available for fulvestrant and Recrudescence
| Article | Year |
|---|---|
[Assessment of the clinical efficacy and safety of fulvestrant in heavily pretreated patients with hormone-receptor positive metastatic breast cancer-a single-institution experience].
Topics: Adult; Aged; Antineoplastic Agents, Hormonal; Breast Neoplasms; Estradiol; Fulvestrant; Humans; Middle Aged; Neoplasm Metastasis; Receptors, Estrogen; Recurrence | 2013 |
[Indoleamine 2,3-Dioxygenase Activity during Fulvestrant Therapy for Aromatase Inhibitor-Resistant Metastatic Breast Cancer].
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Drug Resistance, Neoplasm; Estradiol; Female; Fulvestrant; Humans; Indoleamine-Pyrrole 2,3,-Dioxygenase; Middle Aged; Neoplasm Metastasis; Recurrence | 2015 |
[Indoleamine 2,3-Dioxygenase Activity during Fulvestrant Therapy for Multiple Metastatic Breast Cancer Patients].
Topics: Adult; Antineoplastic Agents, Hormonal; Breast Neoplasms; Disease Progression; Estradiol; Female; Fulvestrant; Humans; Indoleamine-Pyrrole 2,3,-Dioxygenase; Neoplasm Metastasis; Recurrence | 2016 |
Identification of TACC1, NOV, and PTTG1 as new candidate genes associated with endocrine therapy resistance in breast cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Breast Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Estradiol; Female; Fetal Proteins; Fulvestrant; Gene Expression Regulation, Neoplastic; Genes, Neoplasm; Humans; Microtubule-Associated Proteins; Middle Aged; Models, Biological; Neoplasm Proteins; Nephroblastoma Overexpressed Protein; Nuclear Proteins; Phenotype; Prognosis; Recurrence; RNA, Messenger; Securin; Tamoxifen | 2009 |
An in vitro model showing adaptation to long-term oestrogen deprivation highlights the clinical potential for targeting kinase pathways in combination with aromatase inhibition.
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Aromatase Inhibitors; Breast Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Estradiol; Estrogens; Female; Fulvestrant; Gene Expression Profiling; Humans; Insulin-Like Growth Factor I; Models, Biological; Nitriles; Postmenopause; Receptors, Estrogen; Recurrence; Triazoles | 2011 |